

Special Issue

Epigenetic Changes in Cancer: Mechanisms, Biomarkers, and Therapeutic Strategies

Message from the Guest Editor

Cancer is a multifactorial disease in which epigenetic modifications play a crucial role in its initiation, progression, and therapeutic resistance. This Special Issue aims to explore the latest advances in understanding the molecular mechanisms underlying epigenetic changes in cancer, such as DNA methylation, histone modification, and non-coding RNA regulation. We welcome studies identifying novel epigenetic biomarkers with potential for early detection, prognosis, and therapeutic monitoring. Additionally, contributions focusing on the development of innovative epigenetic therapies, including small-molecule inhibitors, gene-editing tools, and combination therapies, are encouraged. The integration of multi-omics approaches and bioinformatics to unravel epigenetic networks in cancer will also be highlighted. By assembling cutting-edge research and reviews, this Special Issue seeks to bridge the gap between basic epigenetic research and translational applications, ultimately advancing precision oncology.

Guest Editor

Dr. Priscilla Brebi-Mieville

1. Laboratory of Integrative Biology (LIBI), Centro de Excelencia en Medicina Traslacional (CEMT), Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco 4810296, Chile
2. Millennium Institute on Immunology and Immunotherapy, Santiago 8331150, Chile
3. BMRC, Biomedical Research Consortium, Santiago 8331150, Chile

Deadline for manuscript submissions

closed (30 April 2026)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/228573

*Current Issues in Molecular
Biology*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.